This is the first study to provide direct experimental evidence proving the significant role of DC EZH2 in FHF, supporting the potential clinical applicability of pharmacological targeting of epigenetic modifications for the treatment of FHF. The gene discussed is EZH2; the disease is TNF receptor 1-associated periodic fever syndrome.